CD8A and neoplasm: In line with this phenotype, the in vivo delivery of miR-34 via MRX34 in our syngeneic tumor model increased the number of tumor-infiltrating CD8+ T-cells and decreased the number of exhausted CD8+PD1+ T-cells, macrophages, and Tregs, suggesting that miR-34 may have a direct effect on immune evasion that can be exploited therapeutically.